Oyster (Crassostrea gigas) hydrolysates produced on a plant scale have antitumor activity and immunostimulating effects in BALB/c mice.
Oyster extracts have been reported to have many bioactive peptides. But the function of oyster peptides produced by proteolysis is still unknown. In this study, the oligopeptide-enriched hydrolysates from oyster (Crassostrea gigas) were produced using the protease from Bacillus sp. SM98011 at laboratory level, and scaled up to pilot (100 L) and plant (1,000 L) levels with the same conditions. And the antitumor activity and immunostimulating effects of the oyster hydrolysates in BALB/c mice were investigated. The growth of transplantable sarcoma-S180 was obviously inhibited in a dose-dependent manner in BALB/c mice given the oyster hydrolysates. Mice receiving 0.25, 0.5 and 1 mg/g of body weight by oral gavage had 6.8%, 30.6% and 48% less tumor growth, respectively. Concurrently, the weight coefficients of the thymus and the spleen, the activity of natural killer (NK) cells, the spleen proliferation of lymphocytes and the phagocytic rate of macrophages in S180-bearing mice significantly increased after administration of the oyster hydrolysates. These results demonstrated that oyster hydrolysates produced strong immunostimulating effects in mice, which might result in its antitumor activity. The antitumor and immunostimulating effects of oyster hydrolysates prepared in this study reveal its potential for tumor therapy and as a dietary supplement with immunostimulatory activity.
Wang
Yu-Kai
YK
State Key Laboratory of Microbial Technology, Marine Biotechnology Research Center, Shandong University, Jinan, 250100, China. dawson82@sina.com
He
Hai-Lun
HL
Wang
Guo-Fan
GF
Wu
Hao
H
Zhou
Bai-Cheng
BC
Chen
Xiu-Lan
XL
Zhang
Yu-Zhong
YZ
D000276:Adjuvants, Immunologic / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D005260:Female; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010125:Ostreidae / Q000737:chemistry*; D010587:Phagocytosis / Q000187:drug effects; D011492:Protein Hydrolysates / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy / Q000276:immunology
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D011492:Protein Hydrolysates
In Vivo. 1998 May-Jun;12(3):305-9
9706475
Int Immunopharmacol. 2009 Jul;9(7-8):931-6
19348966
J Vet Med Sci. 2001 Mar;63(3):269-74
11307926
Immunobiology. 2006;211(5):341-50
16716803
Int Immunopharmacol. 2005 May;5(5):811-20
15778117
J Immunol Methods. 1986 May 22;89(2):271-7
3486233
Science. 1996 Apr 5;272(5258):50-3
8600536
Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8
9918775
Cancer Lett. 2006 Nov 18;243(2):228-34
16410037
Am Surg. 1996 Jan;62(1):14-8
8540639
Appl Environ Microbiol. 2000 Sep;66(9):3898-904
10966406
Int Immunopharmacol. 2008 Jun;8(6):909-15
18442797
Bioresour Technol. 2006 Feb;97(3):385-90
15935656
Immunopharmacology. 1999 Feb;41(2):157-64
10102797
Bioresour Technol. 2002 Aug;84(1):63-8
12137270
Jpn J Cancer Res. 2000 Oct;91(10):1022-7
11050473
Biomed Pharmacother. 1996;50(3-4):149-53
8881371
Biomed Pharmacother. 1997;51(10):427-9
9863500
J Agric Food Chem. 2009 Aug 26;57(16):7159-70
19650628